Active Immunotherapy for Glioblastoma Treatment: A Systematic Review and Meta-Analysis. (16th March 2022)

• Record Type: Journal Article
• Authors: Wahyuhadi, Joni; Immadoel Haq, Irwan Barlian; Arifianto, Muhammad Reza; Sulistyono, Bagus; Meizikri, Rizki; Rosada, Atika; Sigit Prakoeswa, Cita Rosita; Susilo, Rahadian Indarto
• Is Part Of: Cancer control. Volume 29(2022)
• Publication Date: 2022-03-16
• Subjects: active immunotherapy -- vaccine -- high-grade glioma -- glioblastoma -- glioblastoma multiforme; Cancer -- Prevention -- Periodicals; Cancer -- Diagnosis -- Periodicals; Cancer -- Treatment -- Periodicals; Cancer -- Palliative treatment -- Periodicals; Cancer -- Prevention; Medical Oncology; Neoplasms -- prevention & control; Neoplasms -- therapy; Electronic journals; Periodicals; Periodicals; 616.994005
• DOI: 10.1177/10732748221079474
• Languages: English
• ISSNs: 1073-2748

Abstract

Introduction: Glioblastoma multiforme (GBM) makes 60–70% of gliomas and 15% of primary brain tumors. Despite the availability of standard multimodal therapy, 2 years, 3 years, and 5 years survival rate of GBM are still low. Active immunotherapy is a relatively new treatment option for GBM that seems promising. Methods: An electronic database search on PubMed, Cochrane, Scopus, andclinicaltrials.gov was performed to include all relevant studies. This study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA). Reported parameters are OS, PFS, AEs, post treatment KPS, and 2 year mortality. Results: Active immunotherapy provided better OS (HR = .85; 95% CI = .71–1.01; P = .06) and PFS (HS = .83; 95% CI= .66 – 1.03; P = .11) side albeit not statistically significant. Active immunotherapy reduces the risk of 2 year mortality as much as 2.5% compared to control group (NNT and RRR was 56.7078 and 0, 0258, respectively). Conclusion: Active immunotherapy might be beneficial in terms of survival rate in patients with GBM although not statistically significant. It could be a treatment option for GBM in the future.